View Older Stories View More Recent Stories

Jan 2, 2024 07:30AM Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
Dec 13, 2023 07:30AM Theratechnologies (THTX) Announces FDA Approval of Trogarzo
Dec 13, 2023 07:30AM Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
Nov 24, 2023 07:30AM Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
Oct 19, 2023 07:31AM Theratechnologies' (THTX) Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Oct 19, 2023 07:30AM Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
Oct 13, 2023 07:30AM Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Oct 13, 2023 07:01AM Theratechnologies (THTX) Reports Results from Trogarzo Intramuscular Administration Study
Oct 13, 2023 07:00AM Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
Oct 12, 2023 07:30AM Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Oct 4, 2023 07:31AM Theratechnologies (THTX) Receives January 22nd, 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Oct 4, 2023 07:30AM Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Sep 26, 2023 07:30AM Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Sep 25, 2023 07:00AM Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
Sep 20, 2023 07:00AM Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
Sep 18, 2023 04:15PM Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
Sep 7, 2023 01:57PM Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Jul 12, 2022 07:30AM CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montr
Jul 12, 2022 07:30AM CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montr
Jan 25, 2021 09:00AM Piramal Pharma Solutions Announces Sterile Fill/Finish Program with Theratechnologies Inc. for TH1902 Peptide-drug Conjugate
View More Recent Stories View Older Stories